泓博医药：现阶段DiOrion平台药物研发服务直接收入占整体营业收入的比重较小
Pharma Resources (Shanghai) Pharma Resources (Shanghai) (SZ:301230) Mei Ri Jing Ji Xin Wen·2026-01-14 12:12

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) announced that the direct revenue from its DiOrion platform drug development services currently constitutes a small proportion of the company's overall operating income, and it does not significantly impact the company's overall business performance [1] Group 1 - The company reported unusual stock trading fluctuations and severe abnormal trading activity [1] - An internal review found no undisclosed significant information that could have impacted the stock price [1]